As an increasing emphasis continues to be placed on value and patient outcomes, drug makers are being presented with an opportunity to jockey for market share and brand differentiation by staying ahead of the curve when it comes to presenting outcomes data that correlates to therapies.
As an increasing emphasis continues to be placed on value and patient outcomes, drug makers are being presented with an opportunity to jockey for market share and brand differentiation by staying ahead of the curve when it comes to presenting outcomes data that correlate to therapies.
According to a report by the Health Research Institute (HRI) at PwC, health insurers and patients are primarily concerned with the efficacy of drugs and how those drugs will affect total medical costs. With payment shifting to improved patient outcomes, the onus is now put on health organizations to provide clinical evidence of efficacy as well as cost effectiveness. Although this objective can be rigorous, there is an upside for companies that are able to present these data.
HRI’s report, which features survey responses from 100 US health insurers and pharmaceutical benefits managers, identifies “5 major forces” that are altering pharmaceutical revenue models. They are as follows:
To learn more about how these forces are impacting pharmaceutical and life sciences companies, visit the PwC website.
Survival, PROs Favor Cemiplimab Plus Chemotherapy vs Chemotherapy Alone in Advanced NSCLC
December 4th 2023For patients with advanced non–small cell lung cancer (NSCLC), regardless of PD-L1 status, cemiplimab plus chemotherapy had favorable survival benefits and patient-reported outcomes over chemotherapy alone.
Read More
SABCS 2023 Sessions Touch on "Every Aspect of Breast Cancer"
December 4th 2023The 46th annual San Antonio Breast Cancer Symposium will take place December 5-9, with new and experienced attendees able to choose and learn from a schedule overflowing with the latest developments in breast cancer science and research.
Read More